Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Aurora Cannabis's 3-Year RORE % for the quarter that ended in Mar. 2026 was 14.80%.
The industry rank for Aurora Cannabis's 3-Year RORE % or its related term are showing as below:
ACB's 3-Year RORE % is ranked better than 64.35% of 934
companies
in the Drug Manufacturers industry
Industry Median: 3.075
vs ACB: 14.80
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Aurora Cannabis 3-Year RORE % Related Terms
Aurora Cannabis 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Aurora Cannabis's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aurora Cannabis's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurora Cannabis 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aurora Cannabis's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Aurora Cannabis's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Aurora Cannabis (ACB) has a 3-Year RORE % of 14.80 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Aurora Cannabis and its competitors. According to the industry distribution chart, Aurora Cannabis ranks #333 out of 934 companies in the Drug Manufacturers industry, placing it in the top 35.7%.
Is Aurora Cannabis' 3-Year RORE % too high?
Aurora Cannabis' current 3-Year RORE % is 14.80. The Drug Manufacturers industry median 3-Year RORE % is 3.08. Aurora Cannabis' value of 14.80 is 381.3% above this industry median. Based on the distribution chart, Aurora Cannabis ranks #333 out of 934 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aurora Cannabis has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aurora Cannabis' 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aurora Cannabis ranks #333 out of 934 companies for 3-Year RORE %. This puts Aurora Cannabis in the upper half of its industry. The industry median 3-Year RORE % is 3.08. Aurora Cannabis' value of 14.80 is 381.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.08, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurora Cannabis's current 3-Year RORE % of 14.80 is 381.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Aurora Cannabis and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurora Cannabis's current 3-Year RORE % is 14.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurora Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Aurora Cannabis (ACB) is currently considered Possible Value Trap. The stock's GF Value™ is $4.22, compared to a current price of $2.79 — trading 33.9% below its estimated fair value. The current 3-Year RORE % is 14.80 and 381.3% above the Drug Manufacturers industry median of 3.08. Aurora Cannabis' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Aurora Cannabis (ACB), the current 3-Year RORE % is 14.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurora Cannabis (ACB) Overvalued in 2026?
Based on GuruFocus' analysis, Aurora Cannabis stock appears to be undervalued.
The current stock price of $2.79 is trading 33.9% below its estimated GF Value™ of $4.22.
GuruFocus considers Aurora Cannabis to be Possible Value Trap.
Key valuation signals for ACB:
3-Year RORE %: 14.80
GF Value™: $4.22 vs. price of $2.79 (33.9% below fair value)
Industry Position: 381.3% above the Drug Manufacturers median (#333 of 934)
No single metric tells the full story. See the ACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.
59GF Score
Get the complete analysis for ACB
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACB has been successfully added to your 
